The Board is appointed by the Annual General Meeting and has the overall task of managing the Company’s affairs on behalf of its shareholders. The Board continuously assesses the Group’s financial situation and evaluates the operational management.

The Board appoints the CEO and decides on significant changes in the Company’s organization and operations. The Board also ensures that the Company has satisfactory internal control over financial conditions and that information regarding the general and financial development is correctly communicated in its financial reports.

The board can be contacted at the e-mail address styrelse@oasmia.com.

 

Anders Härfstrand

Name: Anders Härfstrand

Title: Chairman of the Board since May 2020, and member of the Board since September 2019. Member of the Remuneration Committee and Audit Committee.

Born: 1956

Education: MD and Ph.D from Karolinska Institutet in Stockholm.

Holdings: 30,000 shares.

Previous experience: Director of Karolinska Development AB from 2017 to 2019 and as Chief Executive Officer of BBB Therapeutics BV from 2014 to 2015. Prior to that, he was President and Chief Executive Officer Europe of Makhteshim Agan Industries Ltd. (now ADAMA); President and Chief Executive Officer of Humabs BioMed SA; and Chief Executive Officer of Nitec Pharma AG (now Horizon Pharmaceuticals). He has also served in various executive roles at Serono, Pfizer and Pharmacia. He has a significant operational global experience of the pharmaceutical industry especially from the US, Japan and Europe.

Other assignments: Chairman of Härfstrand Consulting AG and board member of Prothena Inc.

Independent in relation to Oasmia, the company management and to major shareholders of the company.

Download photo:
Hege Hellström

Name: Hege Hellström

Title: Member of the Board since September 2019. Member of the Audit Committee.

Born: 1965

Education: B.Sc., Medical Laboratory Scientist, 1985, Oslo Metropolitan University, Norway

Holdings: -

Previous experience: Hege worked at the biotechnology company Sobi from 2013 until 2018 and was president for EMENAR (Europe, Middle East, North Africa and Russia). Prior to that, she was globally responsible for the Cardiovascular business area within Sanofi, VP Renal Europe and Head of Regional Liaisons at Sanofi, VP Renal and Endocrine Europe at Genzyme and General Manager Benelux at Genzyme. Before Genzyme, she was 13 years at Baxter.

Other assignments: Founder and manager of Belnor BVBA, a consultancy and investment company. She is also a non-executive Board member at Camurus AB (CAMX.ST), a Swedish biotech company, and Advicenne (Euronext: ADVIC), a French pharmaceutical company.

Independent in relation to Oasmia, the company management and to major shareholders of the company.

Download photo:
Birgit Stattin Norinder

Name: Birgit Stattin Norinder

Title: Member of the Board since May 2020. Chair of the Remuneration Committee.

Born: 1948

Education: M.Sc in Pharmacy from Uppsala University

Holdings: -

Previous experience: Extensive experience from international pharmaceutical and biotechnology companies in Sweden, USA and United Kingdom. Amongst many positions she has served as CEO and Chairman of Profilix Ltd., Senior VP Worldwide Product Development, Pharmacia & Upjohn and Dir. Int. Reg. Affairs Division, Glaxo Group Research Ltd. Birgit has also held several board and chairman positions of European biotechnology companies.

Other assignments: Member of the Board of AddLife AB, Hansa Biopharma AB and Jettesta AB.

Independent in relation to Oasmia, the company management and to major shareholders of the company.

Download photo:
Peter Zonabend

Name: Peter Zonabend

Title: Member of the Board since March 2019. Chair of the Audit Committee.

Born: 1980

Education: LL.M from Stockholm University, EMLE from Erasmus School of Law, Bsc in Business and Economics from Stockholm University and DU EAED from Aix Marseille Université.

Holdings: 500,000 shares. Manages 79,917 shares by proxy.

Previous experience: CEO of Victoria Investments Holding Ltd, 2010-2017, Law Firm Fylgia, Law Firm Björn Rosengren. Board assignments within Hövding Sverige AB, HQ AB, TCER AB, CBD Solutions AB.

Other assignments: CEO Arwidsro, board assignment within Arwidsro.

Independent in relation to Oasmia and company management, not independent of major shareholders in the company.

Download photo: